Quick answer: Most pharma R&D strategy teams use a two-layer stack. The first layer is specialized data: clinical trial registries, pipeline and drug databases, patent databases and scientific literature. The second layer is a competitive intelligence platform that brings those sources together with the company's own research, so teams can search, synthesize and share across therapeutic areas from one place. The data layer tells you what happened. The platform layer is what turns it into a decision.
Key takeaways
- No single data source covers pharma R&D intelligence. Teams combine trial, pipeline, patent, literature and regulatory sources.
- The gap is rarely data. It is getting those sources, plus years of internal research, into one place people can search and trust.
- A competitive intelligence platform sits on top of the data layer and adds unified search, AI synthesis with citations, therapeutic-area views and delivery to non-analysts.
- In pharma, governance decides the shortlist: licensed AI use, document-level permissions, SOC 2 and zero data retention.
Layer 1: the specialized data sources
R&D strategy questions cut across many source types. A typical team draws on:
- Clinical trial registries and results: study design, enrollment, endpoints and readouts.
- Pipeline and drug databases: where competitor assets sit by phase, mechanism and indication.
- Patents: freedom to operate, exclusivity windows and early signals of new programs.
- Scientific literature: peer-reviewed journals, preprints and conference abstracts, often the first public sign of a competitor's direction.
- Regulatory signals: approvals, guidance changes and policy shifts across markets.
- Internal research: prior landscapes, advisory board notes, field intelligence and commissioned studies.
Each of these is valuable on its own. The problem is that they live in separate systems with separate logins and licenses, and the internal research is often the hardest of all to find.
Layer 2: the competitive intelligence platform
The platform layer is where R&D strategy teams spend their time. Its job is to unify the sources above and make them usable. What teams look for:
- One search across licensed, public and internal content: answers a question in minutes instead of checking six systems.
- Therapeutic-area enrichment: scopes results to the mechanisms and indications a team owns.
- AI synthesis with source citations: speeds up landscapes and briefs while keeping every claim checkable.
- Dashboards and alerts: flags competitor trial results and regulatory changes as they happen.
- Delivery beyond analysts: gets intelligence to R&D, medical, commercial and leadership teams.
- Enterprise governance: clears InfoSec in a regulated company.
How R&D strategy teams use the stack day to day
Competitor and trial monitoring. Automated dashboards track competitor pipelines, study results and regulatory changes, so the team reviews what changed instead of re-running searches.
Landscape and portfolio decisions. When leadership asks whether to enter an indication, the team pulls trial activity, patents, literature and internal history into one cited brief.
Scientific literature intelligence. Peer-reviewed research, preprints and abstracts across therapeutic areas flow to R&D and medical teams in near real time.
Compliance and risk monitoring. Policy changes and risk indicators across markets surface early enough to protect launch timelines.
What to watch for when choosing a platform
- AI use-rights. Many licensed sources can be read but not used with a generative model. Ask which sources the platform is licensed to use with AI.
- Citations on every answer. In R&D, an uncited claim does not survive a review meeting.
- Permissions. Early-stage program data should only reach people cleared to see it. Look for document-level permissions inherited from your existing systems.
- Adoption outside the CI team. If only analysts log in, the platform becomes another silo.
Where Northern Light SinglePoint fits
Northern Light SinglePoint is the platform layer. It unifies licensed research from 150+ providers with your internal content and Northern Light's Curated Intelligence Collections, enriches it by therapeutic area, mechanism and indication, and cites every AI answer to its source document. It is SOC 2 certified, inherits SSO and document-level permissions, operates with zero data retention and does not train AI models on customer content. Intelligence reaches teams through dashboards, alerts, briefings and Microsoft Copilot.
A Director of Competitive Intelligence at a top-10 global pharma company described the change this way: before SinglePoint, the team spent days preparing competitive summaries; now it delivers daily briefings across therapeutic areas. Northern Light is a Leader in the 2026 Gartner Magic Quadrant for Competitive and Market Intelligence Platforms.
Learn more on the pharma competitive intelligence page or read the pharma and biotech buyer's guide.
Frequently asked questions
Do pharma R&D teams need a separate CI platform if they already license trial and pipeline databases?
Usually, yes. Databases supply the data; a CI platform unifies them with literature, patents, regulatory signals and internal research, adds cited AI synthesis and delivers results to the teams that decide.
Who in pharma uses a competitive intelligence platform?
R&D strategy, competitive intelligence, medical affairs, business development, commercial and leadership teams. The best platforms give each group a view suited to its role.
How do CI platforms handle confidential pipeline information?
Enterprise platforms inherit document-level permissions from existing systems, so internal program data is only visible to people cleared to see it, and AI answers respect the same permissions.
What is the difference between a CI platform and a general AI assistant?
A general AI assistant reasons over what you give it. A CI platform supplies licensed, permissioned content with the rights to use it with AI, and cites every answer to its source.
Gartner and Magic Quadrant are registered trademarks and service marks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation.
